Navigation Links
Accera, Inc. Announces Results of Phase II Study in Alzheimer's,Disease at American Academy of Neurology Meeting

BROOMFIELD, Colo., May 01, 2007 /PRNewswire/ -- Accera Inc. is presenting topline data today from its Phase IIb study of its lead compound AC-1202 in Alzheimer's disease (AD) at the American Academy of Neurology (AAN) 59th Annual Meeting in Boston. Judged by the AAN to be in the top five percent of the program, the data will also be featured in the Scientific Highlights Plenary Session.

The randomized, double-blinded, placebo-controlled Phase IIb trial evaluated 152 subjects that had previously been diagnosed with mild to moderate AD. Consistent with the findings of Accera's Phase IIa study, subjects who did not have the ApoE4 genotype-a known genetic risk factor that occurs in half of all AD patients-responded particularly well to treatment, as reflected in statistically significant improvement in AD Assessment Scale- Cognitive (ADAS-Cog) scores.

Subjects underwent pharmacogenomic analysis for a variety of genetic markers and were evaluated through a battery of neuropsychometric tests at Day 0, 45, and 90. Compared to the placebo group, the ADAS-Cog scores of the AC- 1202-treated ApoE4(-) population improved 3.5 points in twelve weeks (p=0.01), and statistically significant improvement was seen in just 45 days.

Interestingly, ApoE4(-) subjects who also exhibited a genetic variation that affects glucose regulation showed a 5 point improvement in ADAS-Cog scores compared to placebo, providing further insight into the disease. "The profound effect we see in the population without the ApoE4 risk factor supports the findings of an earlier study linking efficacy to a certain pharmacogenomic profile," said Dr. Lauren Costantini, Accera's vice president of clinical development. "It also provides further evidence of the link between Alzheimer's disease and glucose metabolism."

Regardless of genotype, subjects treated with AC-1202 showed a trend toward improvement (p=.072), suggesting the com pound's disease modifying potential. Taken in addition to an existing AD treatment, AC-1202 was well tolerated, making it a promising co-therapeutic candidate for the chronic treatment of the disease.

Dr. Lauren Costantini is presenting the abstract, "Clinical Efficacy of AC-1202 in Mild to Moderate Alzheimer's Disease" at the Late Breaking Science session today at 3:45 p.m. EDT. The plenary session will be held at 5:15 p.m. EDT on Friday, May 4.

The trial was conducted at 25 centers across the United States, and all subjects were given the opportunity to participate in a six-month open-label extension upon completion of the three-month blinded study. The results of the open-label extension will be presented at the Alzheimer's Association's International Prevention Conference in early June.

About AC-1202

Brain imaging techniques performed on AD patients reveal a dramatically decreased uptake of glucose, the brain's preferred source of energy. AC-1202 is an orally available, liquid compound that is efficiently converted by the liver into ketone bodies, an alternative energy source that the brain can metabolize even when it cannot process glucose. Thus preserving the glucose- deprived brain cells, AC-1202 has disease modifying potential in AD and a number other neurodegenerative diseases characterized by neuronal metabolism. The potentially neuroprotective mechanism of this first-in-class compound is also being evaluated in age-associated memory impairment, Parkinson's disease, and canine cognitive dysfunction.

About Accera, Inc.

Based in Broomfield, CO, Accera, Inc. is a privately held biopharmaceutical company focused on developing novel drugs for neurodegenerative diseases. The company's lead candidate, AC-1202, is a first- in-class molecule currently in Phase II clinical trials for Alzheimer's disease and age-associated memory impairment. A key element of Accera's strategy is to develop AC-1202 and other small molecule com pounds in its pipeline with corporate partners for a range of memory and cognition disorders associated with neurological conditions and aging. www.accerapharma.com

    For information contact:

    Meghan Feeks

    Richard Lewis Communications, Inc.

    212-827-0020

    

mfeeks@rlcinc.com

CONTACT: Meghan Feeks of Richard Lewis Communications, Inc., for AcceraInc. +1-212-827-0020, or mfeeks@rlcinc.com

Web site: http://www.accerapharma.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
2. Accera, Inc. to Present Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... transport experience for the millions of people who require these medical transport services ... industry through the use of technology. Now, SmartEMS has put forth an industry-changing ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):